But Ascletis is the first to publicly file an IND for a once-monthly GLP-1/GIP peptide depot in this round
(NOTE: While Retatrutide itself has not been directly studied for its effects on energy expenditure, the medical literature shows glucagon infusions on its own can increase it in humans all the more reason you should pay attention to the Phase 1 clinical trial measuring calorie consumption in Retatrutide users) Gone was the appetite suppression, and in came the appetite elevation
The revelation came from Jill Furman, director of CDERs Office of Compliance, during the 2025 Enforcement, Litigation, and Compliance Conference, where she addressed enforcement trends and compliance priorities
In a 48-week phase 2 trial published in The New England Journal of Medicine , adults with obesity (without type 2 diabetes) receiving once-weekly subcutaneous retatrutide at the 12 mg amount achieved a least-squares mean body weight reduction of 24.2%, compared with 2.1% in the placebo group [1]
If you recently had a baby, you may experience symptoms like hot flashes and night sweats due to hormonal fluctuations
The Reality of GLP-1 Medication Costs (Brand Name vs